• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Vasopharm - Articles and news items

Vasopharm appoints Irina Antonijevic as new Chief Medical Officer

Industry news / 9 November 2016 / Niamh Louise Marriott, Digital Content Producer

In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203…

Vasopharm enrols first patient in phase III traumatic brain injury trial

Industry news / 8 September 2016 / Niamh Louise Marriott, Digital Content Producer

Vasopharm’s ronopternin (VAS203) will be evaluated for its safety and efficacy as the first patient is enrolled into the nostra phase III (NO Synthase in TRAumatic Brain Injury) trial – a clinical study to assess whether the drug can be used as a initial treatment for moderately to severely injured closed head traumatic brain (TBI) injury patients…

Vasopharm raises EUR 20m to fund Phase III study of VAS203

Industry news / 21 January 2016 / Victoria White

Vasopharm has designed a Phase III registration study in Europe of VAS203 in in moderate to severe traumatic brain injury…